共 23 条
A Back-to-Front Fragment-Based Drug Design Search Strategy Targeting the DFG-Out Pocket of Protein Tyrosine Kinases
被引:28
作者:
Iwata, Hidehisa
[1
]
Oki, Hideyuki
[1
]
Okada, Kengo
[1
]
Takagi, Terufumi
[1
]
Tawada, Michiko
[1
]
Miyazaki, Yasushi
[1
]
Imamura, Shinichi
[2
]
Hori, Akira
[2
]
Lawson, J. David
[3
]
Hixon, Mark S.
[3
]
Kimura, Hiroyuki
[1
]
Miki, Hiroshi
[1
]
机构:
[1] Takeda Pharmaceut Co Ltd, Discovery Res Labs, Fujisawa, Kanagawa 2518555, Japan
[2] Takeda Pharmaceut Co Ltd, Oncol Drug Discovery Unit, Div Pharmaceut Res, Fujisawa, Kanagawa 2518555, Japan
[3] Takeda Calif Inc, San Diego, CA 92121 USA
关键词:
back-to-front;
FBDD;
DFG-out;
VEGFR2;
phosphorylation;
Yonetani-Theorell Plot;
LEAD DISCOVERY;
INHIBITORS;
BINDING;
PHOSPHORYLATION;
D O I:
10.1021/ml3000403
中图分类号:
R914 [药物化学];
学科分类号:
100701 ;
摘要:
We present a straightforward process for the discovery of novel back pocket-binding fragment molecules against protein tyrosine kinases. The approach begins by screening against the nonphosphorylated target kinase with subsequent counterscreening of hits against the phosphorylated enzyme. Back pocket-binding fragments are inactive against the phosphorylated kinase. Fragment molecules are of insufficient size to span both regions of the ATP binding pocket; thus, the outcome is binary (back pocket-binding or hinge-binding). Next, fragments with the appropriate binding profile are assayed in combination with a known hinge-binding fragment and subsequently with a known back pocket-binding fragment. Confirmation of back pocket-binding by Yonetani-Theorell plot analysis progresses candidate fragments to crystallization trials. The method is exemplified by a fragment screening campaign against vascular endothelial growth factor receptor 2, and a novel back pocket-binding fragment is presented.
引用
收藏
页码:342 / 346
页数:5
相关论文